Coherus BioSciences Inc CHRS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:01 PM EST
8.02UNCH (UNCH)
Volume
17,203
Close
8.02quote price arrow down-0.40 (-4.75%)
Volume
719,511
52 week range
5.58 - 14.11
Loading...
  • Open8.43
  • Day High8.51
  • Day Low8.01
  • Prev Close8.42
  • 52 Week High14.11
  • 52 Week High Date08/16/22
  • 52 Week Low5.58
  • 52 Week Low Date12/27/22

Key Stats

  • Market Cap623.779M
  • Shares Out77.78M
  • 10 Day Average Volume0.77M
  • Dividend-
  • Dividend Yield-
  • Beta0.88
  • YTD % Change1.26

KEY STATS

  • Open8.43
  • Day High8.51
  • Day Low8.01
  • Prev Close8.42
  • 52 Week High14.11
  • 52 Week High Date08/16/22
  • 52 Week Low5.58
  • 52 Week Low Date12/27/22
  • Market Cap623.779M
  • Shares Out77.78M
  • 10 Day Average Volume0.77M
  • Dividend-
  • Dividend Yield-
  • Beta0.88
  • YTD % Change1.26

RATIOS/PROFITABILITY

  • EPS (TTM)-3.60
  • P/E (TTM)-2.23
  • Fwd P/E (NTM)-4.25
  • EBITDA (TTM)-241.385M
  • ROE (TTM)-1,657.06%
  • Revenue (TTM)239.061M
  • Gross Margin (TTM)71.56%
  • Net Margin (TTM)-116.54%
  • Debt To Equity (MRQ)-484.38%

EVENTS

  • Earnings Date02/15/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Coherus BioSciences Inc

 

Profile

MORE
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. It operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences Co., Ltd., CIMERLI, a Lucentis...
Dennis Lanfear
Chairman of the Board, President, Chief Executive Officer
McDavid Stilwell
Chief Financial Officer
Address
C/O DENNIS M. LANFEAR
201 REDWOOD SHORES PARKWAY, SUITE 200
Redwood City, CA
94065
United States

Top Peers

SYMBOLLASTCHG%CHG
MOR
MorphoSys AG
5.00-0.06-1.19%
MDXG
MiMedx Group Inc
4.49-0.21-4.47%
PSTX
Poseida Therapeutics Inc
8.42-0.31-3.55%
KPTI
Karyopharm Therapeutics Inc
3.28-0.24-6.82%
AVIR
Atea Pharmaceuticals Inc
4.38-0.15-3.31%